Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is having a strong start to the trading session this morning, and for good reason. The company was the center of an analyst upgrade, leading to excitement among investors and sending the stock on a run for the top. Today, we’ll talk about: The upgrade; what we’re seeing from … Read more
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is having an overwhelmingly strong start to the trading session in the pre-market hours this morning after reporting its financial results for the first quarter, increasing guidance and announcing a name change. Ultimately, the news led to excitement among investors, sending the stock on a run for the top. … Read more
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is having an overwhelmingly rough start to the trading session this morning, and for good reason. The company reported its financial results for the fourth quarter, missing expectations. To make matters worse, the company released guidance that simply didn’t meet up with what investors wanted to see. Today, we’ll talk … Read more
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is having an incredibly strong day in the market today, and for good reason. The company announced that it has paid down a massive amount of debt. Of course, this led to excitement among investors, sending the stock running for the top. Today, we’ll talk about the news, what … Read more
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is having an overwhelmingly strong day in the market today, and for good reason. The company announced its earnings for the third quarter, blowing away expectations and exciting investors. Today, we’ll talk about what we saw from earnings, how the stock reacted in the market, and what we’ll be … Read more
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is having an overwhelmingly strong start to the trading session this morning in the pre-market hours, and for good reason. The company announced that its wholly owned subsidiary, Bausch + Lomb, in conjunction with Nicox S.A., has received FDA approval for a key treatment. Of course, this led to … Read more
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is having an overwhelmingly strong time in the pre-market hours, which is interesting considering that the company reported its second quarter earnings, and while the report showed a further decline in revenue, investors are taking it as positive. As is normally the case, our partners at Trade Ideas were … Read more
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is having a great start to the trading session this morning, and for good reason. The company announced the redemption of Senior Notes. Of course, this led to excitement among investors, causing gains in the value of the stock and prompting our friends at Trade Ideas to alert us … Read more
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced that sale of its iNova Pharmaceuticals business, causing excitement among investors who sent the stock upward. Of course, our partners at Trade Ideas were the first to alert us to … Read more
Mallinckrodt PLC (NYSE: MNK) is having an overwhelmingly rough day in the market today, and for good reason. Citron research has waged an attack against the company, leading to fear among investors and prompting our partners at Trade Ideas to alert us to the movement. At the moment (10:34), MNK is trading at $39.25 per … Read more